Invitae Corp (NVTA) Files 10-K for the Fiscal Year Ended on December 31, 2020

Article's Main Image

Invitae Corp (NVTA, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2020. Invitae Corp is a genetic information company engaged in genetic diagnostics for hereditary disorders. It provides testing for multiple genes including hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. Invitae Corp has a market cap of $7.65 billion; its shares were traded at around $40.130000 with and P/S ratio of 19.29. GuruFocus has detected 3 severe warning signs with Invitae Corp. .

For the last quarter Invitae Corp reported a revenue of $100.4 million, compared with the revenue of $66.29 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $279.6 million, an increase of 29% from last year. For the complete 30-year financial data, please go here.. For the last five years Invitae Corp had an average revenue growth rate of 103% a year.

The reported loss per diluted share was $4.52 for the year, compared with the loss per share of $2.65 in the previous year. The Invitae Corp had an operating margin of -233.25%, compared with the operating margin of -112.59% a year before. The 10-year historical median operating margin of Invitae Corp is -316.61%. The profitability rank of the company is 3 (out of 10).

At the end of the fiscal year, Invitae Corp has the cash and cash equivalents of $124.8 million, compared with $151.4 million in the previous year. The long term debt was $439.7 million, compared with $312.1 million in the previous year. Invitae Corp has a financial strength rank of 5 (out of 10).

Directors and Officers Recent Trades:

  • Chief Commercial Officer Katherine Stueland sold 5,000 shares of NVTA stock on 02/25/2021 at the average price of $39.96. The price of the stock has increased by 0.43% since.
  • Director Geoffrey Crouse sold 10,000 shares of NVTA stock on 02/22/2021 at the average price of $48.62. The price of the stock has decreased by 17.46% since.

For the complete 20-year historical financial data of NVTA, click here.